Pivotal follow-on trial of TMX 101, an intravesicular formulation of imiquimod, in patients with carcinoma in situ bladder cancer

Trial Profile

Pivotal follow-on trial of TMX 101, an intravesicular formulation of imiquimod, in patients with carcinoma in situ bladder cancer

Planning
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2013

At a glance

  • Drugs Imiquimod (Primary)
  • Indications Bladder cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Telormedix
  • Most Recent Events

    • 05 Dec 2013 New trial record
    • 02 Dec 2013 Telormedix has raised Series B financing to support the phase II trial of TMX 101 and finance the planning of a follow on trial, according to a company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top